Slayback Pharma Limited Liability Company Sustainability Profile
Slayback Pharma Limited Liability Company, commonly referred to as Slayback Pharma, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 2017, the company has rapidly established itself in the development and commercialisation of complex generic and specialty pharmaceuticals, focusing on areas such as oncology and neurology. With a commitment to innovation, Slayback Pharma offers a unique portfolio of products that address unmet medical needs, setting them apart in a competitive market. The company has achieved significant milestones, including successful product launches and strategic partnerships, which have bolstered its market position. As Slayback Pharma continues to expand its operational reach, it remains dedicated to improving patient outcomes through high-quality, accessible medications.
DitchCarbon Score
How does Slayback Pharma Limited Liability Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Slayback Pharma Limited Liability Company's score of 28 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Slayback Pharma Limited Liability Company's reported carbon emissions
Slayback Pharma Limited Liability Company, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is identified as a current subsidiary of Azurity Pharmaceuticals, Inc., which may influence its climate-related initiatives and reporting. Despite the lack of direct emissions data, Slayback Pharma's climate commitments and reduction initiatives are not explicitly outlined. There are no documented reduction targets or climate pledges available, suggesting that the company may still be in the early stages of developing a comprehensive sustainability strategy. As a subsidiary, Slayback Pharma may align its environmental goals with those of Azurity Pharmaceuticals, which could include broader industry standards and practices. However, without specific data or commitments, it is challenging to assess their carbon footprint or climate impact accurately. In summary, while Slayback Pharma Limited Liability Company is part of a corporate family that may have climate initiatives, it currently lacks publicly available emissions data and defined reduction targets.
How Carbon Intensive is Slayback Pharma Limited Liability Company's Industry?
How Carbon Intensive is Slayback Pharma Limited Liability Company's Location?
Slayback Pharma Limited Liability Company's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Slayback Pharma Limited Liability Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
